Quantitative assessment of paravalvular regurgitation following transcatheter aortic valve replacement by Crouch, G. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/93102  
 
Gareth Crouch, Phillip J Tully, Jayme Bennetts, Ajay Sinhal, Craig Bradbrook, Amy L Penhall, Carmine 
G De Pasquale, Robert A Baker, and Joseph B Selvanayagam 
Quantitative assessment of paravalvular regurgitation following transcatheter aortic valve 
replacement 
Journal of Cardiovascular Magnetic Resonance, 2015; 17(1):32-1-32-6 
© 2015 Crouch et al.; licensee BioMed Central. This is an Open Access article distributed under the 
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly credited. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this 
article, unless otherwise stated. 




























Crouch et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:32 
DOI 10.1186/s12968-015-0134-0RESEARCH Open AccessQuantitative assessment of paravalvular
regurgitation following transcatheter aortic valve
replacement
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Carmine G De Pasquale1,3, Robert A Baker2,4 and Joseph B Selvanayagam1,3,4*Abstract
Background: Paravalvular aortic regurgitation (PAR) following transcatheter aortic valve implantation (TAVI) is
well acknowledged. Despite improvements, echocardiographic measurement of PAR largely remains qualitative.
Cardiovascular magnetic resonance (CMR) directly quantifies AR with accuracy and reproducibility. We compared
CMR and transthoracic echocardiography (TTE) analysis of pre-operative and post-operative aortic regurgitation in
patients undergoing both TAVI and surgical aortic valve replacement (AVR).
Methods: Eighty-seven patients with severe aortic stenosis undergoing TAVI (56 patients) or AVR were recruited.
CMR (1.5 T) and transthoracic echocardiography (TTE) were carried out pre-operatively and a median of 6 days
post-operatively. The CMR protocol included regurgitant aortic flows using through-plane phase-contrast velocity. None/
trivial, mild, moderate and severe AR by CMR was defined as ≤8%, 9-20%, 21–39%, >40% regurgitant fractions respectively.
Results: Pre- and post-operative left ventricular ejection fraction (LVEF) was similar. Post-procedure aortic regurgitant
fraction using CMR was higher in the TAVI group (TAVI 16 ± 13% vs. AVR 4 ± 4%, p < 0.01). Comparing CMR to TTE,
27 of 56 (48%) TAVI patients had PAR which was at least one grade more severe on CMR than TTE (Z =−4.56, p <0.001).
Sensitivity analysis confirmed the difference in PAR grade between TTE and CMR in the TAVI group (Z = −4.49, p < 0.001).
Conclusion: When compared to CMR based quantitative analysis, TTE underestimated the degree of paravalvular aortic
regurgitation. This underestimation may in part explain the findings of increased mortality associated with mild or
greater AR by TTE in the PARTNER trial. Paravalvular aortic regurgitation post TAVI assessed as mild by TTE may in fact
be more severe.
Keywords: TAVI, Transcatheter, Cardiovascular magnetic resonance, Aortic valve, Paravalvular aortic regurgitationBackground
There now exists extensive registry and clinical trial data
demonstrating an increased incidence of paravalvular aortic
regurgitation (PAR) following transcatheter aortic valve
implantation (TAVI), and consequently, increased mortality
over short term follow-up [1-5]. This is particularly
pronounced when compared to the gold standard surgical
aortic valve replacement (AVR). Despite recent improve-
ments in both hardware and software, transthoracic* Correspondence: joseph.selva@health.sa.gov.au
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regurgitation (PAR) largely remains qualitative. This is
particularly evident in TAVI associated PAR where patient
factors such as airways disease, habitus and prior cardiac
surgery often limit acoustic windows. Additionally the regur-
gitant jets are often multiple and eccentric making traditional
echocardiographic regurgitation assessment techniques
invalid. Despite these profound limitations echocardiog-
raphy is still utilised as the primary assessment tool for
PAR post TAVI. This has prompted the development of
improved and standardized techniques such as those from
the Valve Academic Research Consortium (VARC), how-
ever these have not been validated [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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netic resonance (CMR) is able to directly quantify aortic
regurgitation with high accuracy and reproducibility by
using the technique of phase-contrast velocity mapping.
CMR is not affected by the location, number or nature
of regurgitant jets or thoracic structural patient factors,
and therefore offers an ideal technique for assessing the
severity of TAVI associated PAR. CMR has previously
been well validated in the quantitative assessment of aor-
tic valve regurgitation [7-10]. The assessment of regurgi-
tation severity is identical whether intravalvular or
paravalvular. Furthermore the use of CMR in the early
post-operative after TAVI or AVR to assess both valve
and ventricular function has been validated [11].
To date there has been several studies utilizing CMR flow
imaging to assess PAR in TAVI cohorts. The majority of
these trials have compared CMR assessment to that of either
qualitative or semi-quantitative echocardiography [12-14].
The limitations of these studies include small numbers,
mixed valve types, and discrepant findings. Thus this we
have attempted to address these limitations in our study de-
sign to further validate the use of CMR in PAR assessment
and clarify the incidence of PAR in a single prosthesis type.
In a single-center prospective control trial, we assessed
the extent of PAR in patients undergoing TAVI and
high-risk AVR using this highly accurate and reprodu-
cible CMR technique. We compared the CMR PAR as-
sessment with semi-quantitative TTE assessment, still
the most used technique worldwide. We hypothesized
that TTE would systematically underestimate the severity
of PAR in TAVI patients compared with CMR. Further-
more this underestimation would be more pronounced in
the TAVI group than in the AVR group owing to the com-
plexity of the paravalvular regurgitation.Methods
Ethics
This study was approved by the Human Research
Ethics Committee of Flinders Medical Centre (Ap-
proval No. 237.11, 13 July 2011) and conducted in ac-
cordance with the Declaration of Helsinki. All patients
gave written informed consent.Patient selection
Ninety patients with severe aortic stenosis undergoing
either TAVI or high risk (STS Score >4, euroSCORE > 10)
AVR were enrolled between June 2011 and July 2014. The
decision to proceed with either procedural technique
was made by the heart team at our institution based
on clinical assessment. Three patients were excluded
due to inadequate image quality (2 TAVI, 1 AVR),
leaving 56 TAVI patients and 31 AVR patients (87
total).Procedure technique
All transcatheter valves were Edwards Sapien XT pros-
theses (Edwards Lifesciences, California USA) inserted
via the femoral route. The AVR group all received bio-
prosthetic valves, access being via a median sternotomy
using cardio-pulmonary bypass. Myocardial preservation
and implantation techniques were similar in the surgical
group. Four different tissue valve prostheses were used:
Medtronic Mosaic® - Medtronic Inc, Minnesota USA;
St Jude Medical Epic™ and Trifecta™, St Jude Medical
Inc, Minnesota; Edwards Perimount Magna, Edwards
Lifesciences, California USA.
Imaging techniques
CMR (1.5 T Siemens Aera, Siemens - Germany) and
transthoracic echocardiography (TTE, General Electric
Vivid E9, GE Healthcare - UK) were carried out
pre-operatively and post-operatively at a median of 5
and 6 days for TAVI and AVR respectively. Both CMR
and echo were performed on the same day (consecu-
tively), in random order and analysed by separate blinded
operators.
CMR images were analysed offline using commercially
available software (CVI42, Circle CVI, Alberta, Canada).
The CMR protocol consisted of standard LV short and
long axis views (steady state free precession images) and
forward and regurgitant aortic flows using through-
plane phase-contrast velocity mapping (free breathing,
retrospective gating) (Figure 1). The image plane was
placed 0.5 cm above the aortic valve at end-diastole, but
a position in the aortic root was maintained throughout
the cardiac cycle. The severity of regurgitation by CMR
regurgitant fraction was stratified according to published
criteria: none/trivial <8%, mild 9 - 20%, moderate 21–39%,
and severe >40% [13] [15]. The inclusion of a none/trivial
grading (RF <8%) permits separation of those patients with
clearly no or trivial regurgitation from those with mild
regurgitation, as mild PAR has been demonstrated in the
PARTNER cohort to be clinically significant. Conversion of
CMR regurgitant fraction to a severity grading allowed
direct comparison of imaging techniques.
Echocardiography was performed in the left decubitus
position using commercially available Vivid E9 ultra-
sound machines (General Electric-Vingmed Ultrasound,
Milwaukee, WI, USA). Data were analysed offline using
EchoPAC PC Version 7 (General Electric-Vingmed
Ultrasound) by 2 experienced echocardiography trained
cardiologists. Aortic valve regurgitation was graded
using a combined approach of semi-quantitative and
qualitative parameters. For post-operative assessment
this included visual assessment of the number of jets, jet
width and the circumferential extent for paravalvular
regurgitation, as per existing guidelines and the more re-
cent VARC-2 criteria [6,16]. Regurgitation was classified
Table 1 Patient characteristics
AVR TAVI P
n = 31 n = 56
Age (SD) 80 4 84 6 <.01
Male (%) 15 48 34 61 .27
STS Score (SD) 8.7 7.7 8.9 5.4 .45
Hypertension (%) 26 84 50 90 .47
Previous MI (%) 5 16 12 21 .55
COPD (%) 15 48 23 41 .51
Renal Impairment (%) 11 35 18 32 .76
Atrial Fibrillation (%) 8 26 20 36 .34
Diabetes (%) 15 48 22 39 .42
Redo (%) 0 0 23 41 <.01
Previous CVA/TIA (%) 6 19 17 31 .27
NYHA Class (SD) 2.7 0.6 2.7 0.7 .42
PAH (%) 11 36 14 25 .30
BMI – Body Mass Index; CAD – Coronary Artery Disease; COPD - Chronic
Obstructive Pulmonary Disease; MI – Myocardial Infarction; Neuro CVA- Previous
TIA or CVA; PAH – Pulmonary Artery Hypertension; PCI - Percutaneous coronary
intervention; Redo – Previous Cardiac Surgery; STS – Society of Thoracic
Surgeons Score.
Figure 1 CMR Images (a) LVOT image post TAVI and (b) LVOT Image post AVR.
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Parasternal short and long-axis views and five chamber
views were used to assess the quantity and qualities of
AR jets as well as the extent into the ventricle. Jet width
was measured just below the ventricular side of the valve
stent frame for PAR sufficient to avoid artifact and
graded according to % width of the LVOT. The circum-
ferential extent (%) of PAR was assessed in the paraster-
nal short-axis view and graded according to the
following definition: none/trivial (no or pinpoint jet),
mild (jet <10%), moderate (10%– 29%) and severe
(≥30%) [6]. Aortic flow reversal was assessed from
multiple windows including suprasternal notch and sub-
costal views, and used for both PAR and pre-operative
AR assessment. Pre-operative AR was assessed using
standard imaging techniques [17]. Where disagreement
existed between echocardiographic parameters an
additional blinded assessor was utilised and a consensus
reached.
Statistical analysis
Data analysis was performed with SPSS® 20.0 (SPSS Inc.,
Chicago, IL). Descriptive comparisons between TAVI
and AVR included the independent samples t-test and
the chi-square statistic with Fisher’s exact test as appro-
priate. Agreement between grade of PAR ascertained by
CMR and TTE was estimated with the Wilcoxon
signed-rank test and Bland-Altman analysis. These were
performed separately for TAVI and AVR in sensitivity
analysis. We also applied the Kappa statistics to deter-
mine the agreement on grading of AR severity consistent
with Altiok et al. All statistical tests were two-tailed, an
alpha value p < .05 was considered statistically significant
and no adjustment was made for multiple comparisons.
Results
A total of 87 patients were recruited, 56 TAVI and
31AVR. Although TAVI patients were older, STS scores
were similar between the groups (Table 1). Othercomorbidities were similar except reoperation was more
common in the TAVI group. Early post-operative CMR
and TTE were conducted at a median of 5 days for TAVI
and 6 days for AVR. Mean preoperative left ventricular
(LV) and right ventricular (RV) ejection fractions (EF)
were similar in the 2 groups using CMR (AVR 68% ± 16
vs. TAVI 65% ± 16, p = NS). Post-operative LVEF was
also similar in both groups (AVR 66% ± 16 vs. TAVI
66 ± 16, p = NS).
Pre-procedure aortic valve regurgitation was similar
between AVR and TAVI when compared using CMR regur-
gitant fraction (AVR 14%± 15 vs. TAVI 18 ± 16, p = 0.14).
Comparing pre-procedure aortic valve regurgitation grades
between imaging techniques, CMR and TTE demonstrated
near identical mean values for TAVI (CMR1.1 ± 1.0 vs. TTE
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p = 0.36). All regurgitation was valvular in nature and less
severe than the predominating stenosis. The Wilcoxon
signed-rank test did not indicate a significant difference
between CMR AR grade and TTE (Z = −.323, p = .73).
All post-procedure regurgitation was paravalvular in
nature when assessed by both TTE and intra-operative
transoesophegeal echocardiography (TOE). Post-operative
mean regurgitant fraction using CMR was higher in the
TAVI group when compared to the AVR group (TAVI
16% ± 13 vs. AVR 4%± 4 p < 0.001). In the AVR group
only four patients had PAR, which was mild in the
majority of cases (Table 2).
In the TAVI group 52% of patients (29/56) had semi-
quantitative TTE findings which graded PAR at a differ-
ent value to CMR. In 93% (27/29) of these cases the
PAR was graded at a lesser value by TTE (Z = −4.56,
p < .001). Sensitivity analysis confirmed that the
difference in PAR grade was evident in the TAVI group
(Z = −4.49, p < .001) but not the AVR group (Z = −1.00,
p = .32). The CMR grade (continuous) is plotted by TTE
grade in Figure 2.
Discussion
Our principle findings show that: (1) using CMR quanti-
tative analysis there was significantly more PAR in the
TAVI group than AVR group; (2) semi-quantitative
transthoracic echocardiography underestimates the de-
gree of paravalvular AR when compared to quantitative
CMR; (3) there was no difference between CMR and
TTE in pre-procedure native valvular aortic regurgita-
tion. To the best of our knowledge this is the first time
CMR assessment of TAVI associated PAR has been
reported with a matched surgical AVR control group.
Additionally this is the largest series describing PAR
evaluation using CMR of a single transcatheter valve
type (Edwards Sapien XT), which holds relevance when
transcatheter programs are selecting their preferred
devices.
CMR has been specifically compared to echocardiog-
raphy in the assessment of TAVI associated PAR in three
prior studies. Ribeiro et al. compared CMR and TTE
(VARC-2 criteria) in 42 patients who had EdwardsTable 2 Comparison of post-operative PAR severity
AVR None/Triv. Mild Moderate Severe
CMR 27 (87%) 3 (10%) 1 (3%) 0
Semi-Quant. TTE 28 (90%) 3 (10%) 0 0
TAVI
CMR 15 (26%) 22 (39%) 17 (30%) 3 (5%)
Semi-Quant. TTE 21 (38%) 32 (57%) 1 (2%) 0 (0)%)
Between groups Z = −4.56, p < .001.
Kappa = .41 SE = .07.Sapien XT transcatheter valves, finding TTE underesti-
mated PAR in 62% of cases [14]. Conversely Altiok and
colleagues compared CMR to 2D and 3D TTE (VARC-2
criteria) in 71 patients finding disagreement between
VARC-2 TTE PAR assessment and CMR in only 18% of
patients studied [12]. A smaller study of 16 patients with
the CoreValve prosthesis [18] showed CMR correlated
well with invasive catheter based assessment and poorly
with TTE, which again appeared to underestimate the
regurgitation [18]. Further to the assessment studies of
PAR severity, there is now published data on the poten-
tial clinical consequences the underestimation by TTE
may have. In a small series Hartlage et al. conducted
CMR evaluation in 23 patients with heart failure symp-
toms and PAR post TAVI, finding CMR reclassified the
PAR in nearly 50% of cases [13]. Notwithstanding the
lower incidence of PAR severity in one of these studies
the findings generally concur with those of our prospect-
ive control group study, that even semi-quantitative TTE
assessment significantly underestimates the degree of
PAR. However, our study differs from these prior studies
in also demonstrating the significantly greater incidence
of PAR in TAVI patients compared with a similarly
matched group of AVR patients using quantitative CMR
assessment.
The potential importance of CMR quantification of PAR
is underscored by the finding that, after converting CMR
regurgitant fraction to regurgitant grade, 74% of patients
were classified as having mild or greater PAR. This com-
pares to a range of 21 – 61% reported in prior echocardio-
graphic based studies [19]. Furthermore, our finding that
35% of TAVI patients had moderate or severe PAR,
exceeds the echocardiographic incidence of moderate or
greater PAR in the PARTNER trial reported at 12% [20]
and other trials reported at 3.8 to 13% [21,22]. This poten-
tial systemic underestimation of postoperative PAR by
TTE was supported by several other key findings. Firstly,
48% of TAVI patients had a regurgitant grade lower on
semi-quantitative TTE than CMR. Secondly, the discord-
ance between CMR and TTE was evident by significant
Wilcoxon rank-sum test, and finally sensitivity analysis
corroborated that the difference in TTE and CMR was
constrained only to the TAVI group.
The finding of significant corroboration between CMR
and TTE in the assessment of pre-procedure (native
valve) aortic regurgitation offers two key insights. The
first is that it validates CMR techniques for assessing
aortic valve regurgitation with those of TTE. Secondly it
objectively confirms that the echocardiographic tech-
niques which are readily applicable to native valve or
intravalvular regurgitation are inherently unreliable in
the transcatheter PAR setting. Our findings regarding
pre-procedure regurgitation are supported by earlier
work, which also found consistent agreement between
Figure 2 Correlation CMR regurgitant fraction and semi-quantitative TTE for AVR and TAVI.
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tion [18]. Despite the paucity of data in assessing PAR,
CMR has been well validated in the assessment of aortic
valvular regurgitation [23]. It is recognized as being
highly reproducible, less susceptible to artifact, quantita-
tive and offering concurrent gold standard ventricular
assessment.
Paravalvular aortic regurgitation (PAR) remains a sig-
nificant and underestimated issue for transcatheter
valves despite the impending arrival of third generation
devices. Until TAVI can match surgical PAR rates and
hence reduce associated increased mortality AVR will re-
main first line therapy. Furthermore, there is now a large
population of patients with transcatheter valves who are
affected by mild or greater PAR. It is widely accepted pa-
tients with PAR face increased morbidity and mortality
and there may be an opportunity to intervene either
medically or procedurally should the accurate assess-
ment offered by CMR be broadly adopted [24]. The as-
sociation of mild PAR with increased mortality was a
particularly unexpected finding of the PARTNER trial
[24]. We speculate from our findings that whilst the
causality component of this finding is correct the assess-
ment of mild PAR is not. We suggest that in fact the
mild PAR is in fact moderate or greater in severity and
this occurs as a result of underestimation by transtho-
racic echocardiography.Conclusion
We propose that PAR can be easily, reproducibly and ac-
curately assessed using CMR. The increased incidence of
PAR with TAVI compared to AVR is confirmed using
quantitative CMR assessment. Furthermore we offer a
hypothesis that the association of mortality with mild
AR in the PARTNER trial may be due to limitations of
echocardiography causing underestimation of the degree
of PAR.
Abbreviations
PAR: Paravalvular Aortic Regurgitation; AS: Aortic Stenosis; AVR: Aortic Valve
Replacement; CMR: Cardiovascular Magnetic Resonance; LV: Left Ventricular;
LVEDV: Left Ventricular End-Diastolic Volume; LVESV: Left Ventricular End
Systolic Volume; RV: Right Ventricular; TAVI: Transcatheter Aortic Valve
Replacement; TOE: Transoesophegeal Echocardiography; TTE: Transthoracic
Echocardiography.
Competing interests
Jayme Bennetts is an advisor for Medtronic. Ajay Sinhal is a proctor for
Edwards Lifesciences.
Authors’ contributions
All authors significantly contributed to the content of this original research
article. GC conceived the original study design, undertook data collection,
analysis, interpretation of the results and drafted the manuscript. JB and AS
assisted with study design and made critical review of the manuscript. CB
and AP undertook data collection and provided interpretation of CMR and
echocardiographic data. PT provided statistical analysis and made critical review
of the manuscript. CDP assisted with data interpretation and provided critical
review of the manuscript. Associate RAB and JBS conceived the original study
design, made an interpretation of the data and critical revision of the
manuscript. All authors read and approved the final manuscript.
Crouch et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:32 Page 6 of 6Funding
Funding was provided in the form of unencumbered research grants from
St. Jude Medical and Edwards Lifesciences.
Author details
1South Australian Health and Medical Research Institute, Adelaide, Australia.
2Department of Cardiothoracic Surgery, Flinders Medical Centre, Adelaide,
Australia. 3Department of Cardiology, Flinders Medical Centre, Flinders Drive,
Bedford Park, Adelaide, SA 5042, Australia. 4Flinders University of South
Australia, Adelaide, SA, Australia.
Received: 12 August 2014 Accepted: 15 April 2015
References
1. Gotzmann M, Korten M, Bojara W, Lindstaedt M, Rahlmann P, Mugge A,
et al. Long-term outcome of patients with moderate and severe prosthetic
aortic valve regurgitation after transcatheter aortic valve implantation. Am J
Cardiol. 2012;110:1500–6.
2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter versus surgical aortic-valve replacement in high-risk patients.
N Engl J Med. 2011;364:2187–98.
3. Ussia GP, Barbanti M, Petronio AS, Tarantini G, Ettori F, Colombo A, et al.
Transcatheter aortic valve implantation: 3-year outcomes of self-expanding
CoreValve prosthesis. Eur Heart J. 2012;33:969–76.
4. Vasa-Nicotera M, Sinning JM, Chin D, Lim TK, Spyt T, Jilaihawi H, et al.
Impact of paravalvular leakage on outcome in patients after transcatheter
aortic valve implantation. JACC Cardiovasc Interv. 2012;5:858–65.
5. Webb JG, Wood DA. Current status of transcatheter aortic valve
replacement. J Am Coll Cardiol. 2012;60:483–92.
6. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone
EH, et al. Updated standardized endpoint definitions for transcatheter aortic
valve implantation: the Valve Academic Research Consortium-2 consensus
document (VARC-2). Eur J Cardiothorac Surg. 2012;42:S45–60.
7. Gelfand EV, Hughes S, Hauser TH, Yeon SB, Goepfert L, Kissinger KV, et al.
Severity of mitral and aortic regurgitation as assessed by cardiovascular
magnetic resonance: optimizing correlation with Doppler
echocardiography. J Cardiovasc Magn Reson. 2006;8:503–7.
8. Globits S, Higgins CB. Assessment of valvular heart disease by magnetic
resonance imaging. Am Heart J. 1995;129:369–81.
9. Myerson SG, d’Arcy J, Mohiaddin R, Greenwood JP, Karamitsos TD, Francis
JM, et al. Aortic regurgitation quantification using cardiovascular magnetic
resonance: association with clinical outcome. Circulation. 2012;126:1452–60.
10. Sondergaard L, Lindvig K, Hildebrandt P, Thomsen C, Stahlberg F, Joen T,
et al. Quantification of aortic regurgitation by magnetic resonance velocity
mapping. Am Heart J. 1993;125:1081–90.
11. Crouch G, Bennetts J, Sinhal A, Tully PJ, Leong DP, Bradbrook C, et al. Early
effects of transcatheter aortic valve implantation and aortic valve
replacement on myocardial function and aortic valve hemodynamics:
Insights from cardiovascular magnetic resonance imaging. J Thorac
Cardiovasc Surg. 2015;149(2):462–70
12. Altiok E, Frick M, Meyer CG, Al Ateah G, Napp A, Kirschfink A, et al.
Comparison of two- and three-dimensional transthoracic echocardiography
to cardiac magnetic resonance imaging for assessment of paravalvular
regurgitation after transcatheter aortic valve implantation. Am J Cardiol.
2014;113:1859–66.
13. Hartlage GR, Babaliaros VC, Thourani VH, Hayek S, Chrysohoou C,
Ghasemzadeh N, et al. The role of cardiovascular magnetic resonance in
stratifying paravalvular leak severity after transcatheter aortic valve
replacement: an observational outcome study. J Cardiovasc Magn Reson.
2014;16:93.
14. Ribeiro HB, Le Ven F, Larose E, Dahou A, Nombela-Franco L, Urena M, et al.
Cardiac magnetic resonance versus transthoracic echocardiography for the
assessment and quantification of aortic regurgitation in patients undergoing
transcatheter aortic valve implantation. Heart. 2014;100:1924–32.
15. Gabriel RS, Renapurkar R, Bolen MA, Verhaert D, Leiber M, Flamm SD, et al.
Comparison of severity of aortic regurgitation by cardiovascular magnetic
resonance versus transthoracic echocardiography. Am J Cardiol.
2011;108:1014–20.
16. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn
PA, et al. Recommendations for evaluation of prosthetic valves withechocardiography and doppler ultrasound: a report From the American
Society of Echocardiography’s Guidelines and Standards Committee and
the Task Force on Prosthetic Valves, developed in conjunction with the
American College of Cardiology Cardiovascular Imaging Committee, Cardiac
Imaging Committee of the American Heart Association, the European
Association of Echocardiography, a registered branch of the European
Society of Cardiology, the Japanese Society of Echocardiography and the
Canadian Society of Echocardiography, endorsed by the American
College of Cardiology Foundation, American Heart Association, European
Association of Echocardiography, a registered branch of the European
Society of Cardiology, the Japanese Society of Echocardiography, and
Canadian Society of Echocardiography. J Am Soc Echocardiogr.
2009;22:975–1014. quiz 1082.
17. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA,
et al. Recommendations for evaluation of the severity of native valvular
regurgitation with two-dimensional and Doppler echocardiography. J Am
Soc Echocardiogr. 2003;16:777–802.
18. Sherif MA, Abdel-Wahab M, Beurich HW, Stocker B, Zachow D, Geist V,
et al. Haemodynamic evaluation of aortic regurgitation after transcatheter
aortic valve implantation using cardiovascular magnetic resonance.
EuroIntervention. 2011;7:57–63.
19. Genereux P, Cohen DJ, Mack M, Rodes-Cabau J, Yadav M, Xu K, et al.
Incidence, predictors, and prognostic impact of late bleeding complications after
transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64:2605–15.
20. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter aortic-valve implantation for aortic stenosis in patients who
cannot undergo surgery. N Engl J Med. 2010;363:1597–607.
21. Gotzmann M, Pljakic A, Bojara W, Lindstaedt M, Ewers A, Germing A, et al.
Transcatheter aortic valve implantation in patients with severe symptomatic
aortic valve stenosis-predictors of mortality and poor treatment response.
Am Heart J. 2011;162:238–245.e1.
22. Takagi K, Latib A, Al-Lamee R, Mussardo M, Montorfano M, Maisano F,
et al. Predictors of moderate-to-severe paravalvular aortic regurgitation
immediately after CoreValve implantation and the impact of postdilatation.
Catheter Cardiovasc Interv. 2011;78:432–43.
23. Myerson SG. Heart valve disease: investigation by cardiovascular magnetic
resonance. J Cardiovasc Magn Reson. 2012;14:7.
24. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al.
Two-year outcomes after transcatheter or surgical aortic-valve replacement.
N Engl J Med. 2012;366:1686–95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
